Funding-NIH - Partnerships for Biodefense (R01); June 2, 2013

Agency

National Institute of Allergy and Infectious Diseases

Description

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), supports extramural research focused on understanding, controlling and preventing diseases caused by virtually all infectious agents. In response to threats presented by bioterrorism and emerging infectious diseases, the NIAID Division of Microbiology and Infectious Diseases (DMID) has established research programs to facilitate development of countermeasures for certain pathogens and toxins.

With this FOA, the NIAID invites research applications for projects focused on preclinical development of lead candidate therapeutics, vaccines, or medical diagnostics that address NIAID Category A, B, or C priority pathogens and toxins (agents) (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm). This FOA also invites research applications for projects focused on preclinical development of candidate technologies (including adjuvants) that would improve vaccine effectiveness and/or simplify vaccine delivery to patient populations during a natural outbreak of an infectious disease or following the intentional release of an infectious agent. For the purpose of this FOA, “lead candidate” is defined as a candidate product or technology for which proof-of-concept data have been obtained and “preclinical development” is defined as all activities beyond lead candidate identification (therapeutics or vaccines) or assay/platform/prototype development (diagnostics or vaccine technologies). Examples of supported research areas may include: lead optimization; efficacy testing, safety evaluation; stability testing; manufacturing; adaptation of products or platform technologies to biodefense applications; development of broad spectrum platforms and/or production technologies; optimization of products or technologies; process development; scale-up; production of quantities sufficient for preclinical regulatory requirements; and diagnostic validation. Priority will be given to projects that address the greatest clinical need.

Activity Code: R01 Research Project Grant

Announcement Number: RFA-AI-13-013

Due Date(s): Letter of Intent: June 2, 2013; Application: July 2, 2013

Link to Full Announcement

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-013.html